The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.
Sofia Agelaki
No relevant relationships to disclose
Antonia Kalykaki
No relevant relationships to disclose
Haris Markomanolaki
No relevant relationships to disclose
Galatea Kallergi
No relevant relationships to disclose
Kostas Kalbakis
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline